news3 June 2021 | By Hannah Balfour (European Pharmaceutical Review)
A Phase I/II trial will enrol 150 individuals already vaccinated against COVID-19 with one vaccine and assess the safety and immunogenicity of a booster dose of a different COVID-19 vaccine.